In 2017, Saha et al. demonstrated that the triple-combination therapy of anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4, anti-PD-1, and G47Δ-mIL12 (oncolytic HSV expressing murine IL-12) healed most mice in two glioma models. Here, PDCD1 is linked to central nervous system cancer.